Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) Cancer Antibody Drug Conjugates Market Research Report 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Major Manufacturers Covered in This Report
    • 1.3 Market Segment by Type
      • 1.3.1 Global Cancer Antibody Drug Conjugates Market Size Growth Rate by Type (2019-2025)
      • 1.3.2 First & Second Generation ADCs
      • 1.3.3 Third Generation ADCs
    • 1.4 Market Segment by Application
      • 1.4.1 Global Cancer Antibody Drug Conjugates Market Share by Application (2019-2025)
      • 1.4.2 Hospitals
      • 1.4.3 Clinics
      • 1.4.4 Other
    • 1.5 Study Objectives
    • 1.6 Years Considered

    2 Global Growth Trends

    • 2.1 Global Cancer Antibody Drug Conjugates Market Size
      • 2.1.1 Global Cancer Antibody Drug Conjugates Revenue 2014-2025
      • 2.1.2 Global Cancer Antibody Drug Conjugates Sales 2014-2025
    • 2.2 Cancer Antibody Drug Conjugates Growth Rate by Regions
      • 2.2.1 Global Cancer Antibody Drug Conjugates Sales by Regions 2014-2019
      • 2.2.2 Global Cancer Antibody Drug Conjugates Revenue by Regions 2014-2019
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers

    3 Market Share by Manufacturers

    • 3.1 Cancer Antibody Drug Conjugates Sales by Manufacturers
      • 3.1.1 Cancer Antibody Drug Conjugates Sales by Manufacturers 2014-2019
      • 3.1.2 Cancer Antibody Drug Conjugates Sales Market Share by Manufacturers 2014-2019
    • 3.2 Revenue by Manufacturers
      • 3.2.1 Cancer Antibody Drug Conjugates Revenue by Manufacturers (2014-2019)
      • 3.2.2 Cancer Antibody Drug Conjugates Revenue Share by Manufacturers (2014-2019)
      • 3.2.3 Global Cancer Antibody Drug Conjugates Market Concentration Ratio (CR5 and HHI)
    • 3.3 Cancer Antibody Drug Conjugates Price by Manufacturers
    • 3.4 Key Manufacturers Cancer Antibody Drug Conjugates Plants/Factories Distribution and Area Served
    • 3.5 Date of Key Manufacturers Enter into Cancer Antibody Drug Conjugates Market
    • 3.6 Key Manufacturers Cancer Antibody Drug Conjugates Product Offered
    • 3.7 Mergers & Acquisitions, Expansion Plans

    4 Market Size by Type

    • 4.1 Sales and Revenue for Each Type
      • 4.1.1 First & Second Generation ADCs Sales and Revenue (2014-2019)
      • 4.1.2 Third Generation ADCs Sales and Revenue (2014-2019)
    • 4.2 Global Cancer Antibody Drug Conjugates Sales Market Share by Type
    • 4.3 Global Cancer Antibody Drug Conjugates Revenue Market Share by Type
    • 4.4 Cancer Antibody Drug Conjugates Price by Type

    5 Market Size by Application

    • 5.1 Overview
    • 5.2 Global Cancer Antibody Drug Conjugates Sales by Application

    6 United States

    • 6.1 United States Cancer Antibody Drug Conjugates Breakdown Data by Company
    • 6.2 United States Cancer Antibody Drug Conjugates Breakdown Data by Type
    • 6.3 United States Cancer Antibody Drug Conjugates Breakdown Data by Application

    7 European Union

    • 7.1 European Union Cancer Antibody Drug Conjugates Breakdown Data by Company
    • 7.2 European Union Cancer Antibody Drug Conjugates Breakdown Data by Type
    • 7.3 European Union Cancer Antibody Drug Conjugates Breakdown Data by Application

    8 China

    • 8.1 China Cancer Antibody Drug Conjugates Breakdown Data by Company
    • 8.2 China Cancer Antibody Drug Conjugates Breakdown Data by Type
    • 8.3 China Cancer Antibody Drug Conjugates Breakdown Data by Application

    9 Rest of World

    • 9.1 Rest of World Cancer Antibody Drug Conjugates Breakdown Data by Company
    • 9.2 Rest of World Cancer Antibody Drug Conjugates Breakdown Data by Type
    • 9.3 Rest of World Cancer Antibody Drug Conjugates Breakdown Data by Application
    • 9.4 Rest of World Cancer Antibody Drug Conjugates Breakdown Data by Countries
      • 9.4.1 Rest of World Cancer Antibody Drug Conjugates Sales by Countries
      • 9.4.2 Rest of World Cancer Antibody Drug Conjugates Revenue by Countries
      • 9.4.3 Japan
      • 9.4.4 Korea
      • 9.4.5 India
      • 9.4.6 Southeast Asia

    10 Company Profiles

    • 10.1 Novartis
      • 10.1.1 Novartis Company Details
      • 10.1.2 Company Description and Business Overview
      • 10.1.3 Sales, Revenue and Market Share of Cancer Antibody Drug Conjugates
      • 10.1.4 Cancer Antibody Drug Conjugates Product Introduction
      • 10.1.5 Novartis Recent Development
    • 10.2 Merck
      • 10.2.1 Merck Company Details
      • 10.2.2 Company Description and Business Overview
      • 10.2.3 Sales, Revenue and Market Share of Cancer Antibody Drug Conjugates
      • 10.2.4 Cancer Antibody Drug Conjugates Product Introduction
      • 10.2.5 Merck Recent Development
    • 10.3 Roche
      • 10.3.1 Roche Company Details
      • 10.3.2 Company Description and Business Overview
      • 10.3.3 Sales, Revenue and Market Share of Cancer Antibody Drug Conjugates
      • 10.3.4 Cancer Antibody Drug Conjugates Product Introduction
      • 10.3.5 Roche Recent Development
    • 10.4 AbbVie
      • 10.4.1 AbbVie Company Details
      • 10.4.2 Company Description and Business Overview
      • 10.4.3 Sales, Revenue and Market Share of Cancer Antibody Drug Conjugates
      • 10.4.4 Cancer Antibody Drug Conjugates Product Introduction
      • 10.4.5 AbbVie Recent Development
    • 10.5 UCB
      • 10.5.1 UCB Company Details
      • 10.5.2 Company Description and Business Overview
      • 10.5.3 Sales, Revenue and Market Share of Cancer Antibody Drug Conjugates
      • 10.5.4 Cancer Antibody Drug Conjugates Product Introduction
      • 10.5.5 UCB Recent Development
    • 10.6 Bristol-Myers Squibb
      • 10.6.1 Bristol-Myers Squibb Company Details
      • 10.6.2 Company Description and Business Overview
      • 10.6.3 Sales, Revenue and Market Share of Cancer Antibody Drug Conjugates
      • 10.6.4 Cancer Antibody Drug Conjugates Product Introduction
      • 10.6.5 Bristol-Myers Squibb Recent Development
    • 10.7 Stem CentRx
      • 10.7.1 Stem CentRx Company Details
      • 10.7.2 Company Description and Business Overview
      • 10.7.3 Sales, Revenue and Market Share of Cancer Antibody Drug Conjugates
      • 10.7.4 Cancer Antibody Drug Conjugates Product Introduction
      • 10.7.5 Stem CentRx Recent Development
    • 10.8 Biogen Idec
      • 10.8.1 Biogen Idec Company Details
      • 10.8.2 Company Description and Business Overview
      • 10.8.3 Sales, Revenue and Market Share of Cancer Antibody Drug Conjugates
      • 10.8.4 Cancer Antibody Drug Conjugates Product Introduction
      • 10.8.5 Biogen Idec Recent Development
    • 10.9 Nordic Nanovector
      • 10.9.1 Nordic Nanovector Company Details
      • 10.9.2 Company Description and Business Overview
      • 10.9.3 Sales, Revenue and Market Share of Cancer Antibody Drug Conjugates
      • 10.9.4 Cancer Antibody Drug Conjugates Product Introduction
      • 10.9.5 Nordic Nanovector Recent Development
    • 10.10 Millennium
      • 10.10.1 Millennium Company Details
      • 10.10.2 Company Description and Business Overview
      • 10.10.3 Sales, Revenue and Market Share of Cancer Antibody Drug Conjugates
      • 10.10.4 Cancer Antibody Drug Conjugates Product Introduction
      • 10.10.5 Millennium Recent Development
    • 10.11 Biotest AG
    • 10.12 PDL BioPharma
    • 10.13 Progenics Pharmaceuticals
    • 10.14 Seattle Genetics
    • 10.15 Viventia Biotechnologies
    • 10.16 AbGenomics Corporation
    • 10.17 Helix BioPharma

    11 Value Chain and Sales Channels Analysis

    • 11.1 Value Chain Analysis
    • 11.2 Sales Channels Analysis
      • 11.2.1 Cancer Antibody Drug Conjugates Sales Channels
      • 11.2.2 Cancer Antibody Drug Conjugates Distributors
    • 11.3 Cancer Antibody Drug Conjugates Customers

    12 Market Forecast

    • 12.1 Global Cancer Antibody Drug Conjugates Sales and Revenue Forecast 2019-2025
    • 12.2 Global Cancer Antibody Drug Conjugates Sales Forecast by Type
    • 12.3 Global Cancer Antibody Drug Conjugates Sales Forecast by Application
    • 12.4 Cancer Antibody Drug Conjugates Forecast by Regions
      • 12.4.1 Global Cancer Antibody Drug Conjugates Sales Forecast by Regions 2019-2025
      • 12.4.2 Global Cancer Antibody Drug Conjugates Revenue Forecast by Regions 2019-2025
    • 12.5 United States Market Forecast
    • 12.6 European Union Market Forecast
    • 12.7 China Market Forecast
    • 12.8 Rest of World
      • 12.8.1 Japan
      • 12.8.2 Korea
      • 12.8.3 India

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Research Methodology
        • 14.1.1 Methodology/Research Approach
          • 14.1.1.1 Research Programs/Design
          • 14.1.1.2 Market Size Estimation
          • 14.1.1.3 Market Breakdown and Data Triangulation
        • 14.1.2 Data Source
          • 14.1.2.1 Secondary Sources
          • 14.1.2.2 Primary Sources
      • 14.2 Author Details

      In 2019, the market size of Cancer Antibody Drug Conjugates is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
      In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Cancer Antibody Drug Conjugates.

      This report studies the global market size of Cancer Antibody Drug Conjugates, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
      This study presents the Cancer Antibody Drug Conjugates sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
      For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

      In global market, the following companies are covered:
      Novartis
      Merck
      Roche
      AbbVie
      UCB
      Bristol-Myers Squibb
      Stem CentRx
      Biogen Idec
      Nordic Nanovector
      Millennium
      Biotest AG
      PDL BioPharma
      Progenics Pharmaceuticals
      Seattle Genetics
      Viventia Biotechnologies
      AbGenomics Corporation
      Helix BioPharma

      Market Segment by Product Type
      First & Second Generation ADCs
      Third Generation ADCs

      Market Segment by Application
      Hospitals
      Clinics
      Other

      Key Regions split in this report: breakdown data for each region.
      United States
      China
      European Union
      Rest of World (Japan, Korea, India and Southeast Asia)

      The study objectives are:
      To analyze and research the Cancer Antibody Drug Conjugates status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
      To present the key Cancer Antibody Drug Conjugates manufacturers, presenting the sales, revenue, market share, and recent development for key players.
      To split the breakdown data by regions, type, companies and applications
      To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
      To identify significant trends, drivers, influence factors in global and regions
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

      In this study, the years considered to estimate the market size of Cancer Antibody Drug Conjugates are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      Buy now